BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27502326)

  • 1. A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy.
    Kim KI; Shin MS; Ihm SH; Youn HJ; Sung KC; Chae SC; Nam CW; Seo HS; Park SM; Rhee MY; Kim MH; Cha KS; Kim YJ; Kim JJ; Chun KJ; Yoo BS; Park S; Shin ES; Kim DS; Il Kim D; Kim KH; Joo SJ; Jeong JO; Shin J; Kim CH
    Clin Ther; 2016 Oct; 38(10):2159-2170. PubMed ID: 27502326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
    Lee HY; Kim YJ; Ahn T; Youn HJ; Chull Chae S; Seog Seo H; Kim KS; Rhee MY; Choi DJ; Kim JJ; Chun KJ; Yoo BS; Park JS; Oh SK; Kim DS; Kwan J; Ahn Y; Bae Park J; Jeong JO; Hyon MS; Cho EJ; Han KR; Kim DI; Joo SJ; Shin JH; Sung KC; Jeon ES
    Clin Ther; 2015 Nov; 37(11):2581-2596.e3. PubMed ID: 25850881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
    Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
    Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1705-19. PubMed ID: 22853848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study).
    Chung WB; Ihm SH; Jang SW; Her SH; Park CS; Lee JM; Chang K; Jeon DS; Yoo KD; Seung KB
    Drug Des Devel Ther; 2020; 14():347-360. PubMed ID: 32158190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
    Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
    Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study.
    Kang SM; Youn JC; Chae SC; Park CG; Yang JY; Kim MH; Hong TJ; Kim CH; Kim JJ; Shin DG; Jeong JW; Yoon JH; Park SH; Kwon J; Cho SY
    Clin Ther; 2011 Dec; 33(12):1953-63. PubMed ID: 22136978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicenter, Phase III Study.
    Hong SJ; Jeong HS; Han SH; Chang KY; Hong BK; Lee BK; Chae SC; Kim WS; Park CG; Heo JH; Lee SU; Kim YD; Kim KS; Choi JH; Kang HJ; Kim JJ; Kang SM; Choi YJ; Shin JH; Chun KJ; Shin DG; Park SH; Kwan J; Choi YJ; Jeong MH; Chae JK; Kim DW; Cho JR; Han KR; Won KH; Park SH; Lee SK; Kim SH; Jung J; Kim CH
    Clin Ther; 2017 Oct; 39(10):2049-2060. PubMed ID: 28939406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension.
    Volpe M; Junren Z; Maxwell T; Rodriguez A; Gamboa R; Gomez-Fernandez P; Ortega-Gonzalez G; Matadamas N; Rodriguez F; Dass B; Kyle C; Clarysse L; Bryce A; Moreno-Heredia E; Germano G; Gilles L; Smith RD; Sanderson JE;
    Clin Ther; 2003 May; 25(5):1469-89. PubMed ID: 12867222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial.
    Sohn IS; Kim CJ; Ahn T; Youn HJ; Jeon HK; Ihm SH; Cho EJ; Chung WB; Chae SC; Kim WS; Nam CW; Park SM; Choi JY; Kim YK; Hong TJ; Lee HY; Cho JH; Shin ES; Yoon JH; Yang TH; Jeong MH; Lee JH; Park JI
    Clin Ther; 2017 Aug; 39(8):1628-1638. PubMed ID: 28734660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.
    Rhee MY; Baek SH; Kim W; Park CG; Park SW; Oh BH; Kim SH; Kim JJ; Shin JH; Yoo BS; Rim SJ; Ha JW; Doh JH; Ahn Y; Chae JK; Park JB; Kim SK; Kim CH
    Drug Des Devel Ther; 2015; 9():2847-54. PubMed ID: 26082615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study.
    Sung KC; Oh YS; Cha DH; Hong SJ; Won KH; Yoo KD; Rha SW; Ahn YK; Ahn JC; Jang JY; Hong TJ; Cho SK; Park SH; Hyon MS; Nam CW; Chae IH; Yoo BS; Song JM; Jeong JO; Yoon YW; Kim BS; Yang TH; Cho DK; Kim SH; Choi YJ; Ahn JH; Jeon DW; Kim HS
    Clin Ther; 2018 Jan; 40(1):50-63.e3. PubMed ID: 29248384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.